The “FoundationFocus CDx BRCA LOH” is designed to detect the presence of mutations in the BRCA1/2 genes and the percentage of the genome affected by LOH in DNA from tumor tissue samples of patients with ovarian cancer. This evidence concerns the gene BRCA1 and ovarian carcinoma.